Skip to main content

Traws Pharma, Inc.

corporate_fare Company Profile

Traws Pharma, Inc.

TRAW·NASDAQ·Life Sciences·CIK 0001130598

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing new treatments for respiratory viral diseases. The company is advancing investigational antiviral agents designed to be potent against difficult-to-treat or resistant virus strains, with an emphasis on safety and simple dosing. On April 1, 2024, Traws Pharma, then known as Onconova Therapeutics, Inc., merged with Trawsfynydd Therapeutics, Inc., a privately-held biotechnology company. Before the merger, the company's business focused on discovering and developing cancer treatments. After the merger, the business expanded to include developing therapies for respiratory viral diseases. Following the merger, Traws Pharma has four clinical programs. These include tivoxavir marboxil, an investigational oral, small molecule CAP-dependent endonuclease inhibitor intended as a single-dose treatment for bird flu and seasonal influenza. Tivoxavir marboxil works by inhibiting the cap-dependent endonuclease (CEN) enzyme, which is crucial for influenza virus replication, thereby impeding replication of influenza A or B and bird flu viral strains. Another program is ratutrelvir, an inhibitor of the main protease (3CL protease) of the SAR-CoV-2 virus, which causes COVID-19. The company also continues to develop narazaciclib (ON 123300), a multi-targeted kinase inhibitor for solid tumors and hematological malignancies, used alone or with other anti-cancer therapies, and rigosertib, investigated alone or in combination for various cancers.

Traws Pharma, Inc. (NASDAQ:TRAW) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 33 items for TRAW at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Prospectus Filed for Resale of 35.9 Million Shares, Enabling Massive Dilution
  • Traws Pharma Reports Q1 Net Loss, Zero Revenue, and Going Concern Warning Amidst Highly Dilutive Financing
  • Traws Pharma Reports Q1 Loss, Confirms $60M Financing Extends Runway to Q1 2027
  • Traws Pharma Q1 Revenue Estimate Plunges to $0, Signaling Major Operational Halt
  • Traws Pharma Registers Over 35 Million Shares for Resale, Signaling Significant Potential Dilution

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.79M
Net Income
$9.17M
Diluted EPS
$0.82
Op. Cash Flow
-$18.18M
Free Cash Flow
-$20.77M
Operating Income
-$17.88M
Cash & Equivalents
$3.82M
Debt / Equity
0.00×
Net Margin
328.7%
Shares Outstanding
9.07M sh
Source: 10-K · filed 2026-04-30 · accession 0001104659-26-053041
$0.165 -5.71% today
52-week range · as of 2026-11-16 $0.165 – $3.23
Market cap
$2.69M
Volume
382K (2.0× avg)
3-mo avg 187K
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TRAW - Filings & News (Page 2)

TRAW
May 15, 2026, 5:10 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $1.82
Real-time Price: $0.165 info
Change: -$1.66 (-91%) info
Market Cap: $2.689M info
TRAW
May 15, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.65
Real-time Price: $0.165 info
Change: -$1.48 (-90%) info
Market Cap: $2.689M info
TRAW
May 15, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.65
Real-time Price: $0.165 info
Change: -$1.48 (-90%) info
Market Cap: $2.689M info
TRAW
May 11, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $2.17
Real-time Price: $0.165 info
Change: -$2.01 (-92%) info
Market Cap: $2.689M info
TRAW
May 08, 2026, 5:03 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $2.14
Real-time Price: $0.165 info
Change: -$1.98 (-92%) info
Market Cap: $2.689M info
TRAW
May 05, 2026, 6:55 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $1.54
Real-time Price: $0.165 info
Change: -$1.38 (-89%) info
Market Cap: $2.689M info
TRAW
Apr 28, 2026, 9:41 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $0.165 info
Change: -$1.05 (-86%) info
Market Cap: $2.689M info
TRAW
Apr 15, 2026, 4:47 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.28
Real-time Price: $0.165 info
Change: -$1.11 (-87%) info
Market Cap: $2.689M info
TRAW
Apr 15, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.30
Real-time Price: $0.165 info
Change: -$1.13 (-87%) info
Market Cap: $2.689M info
TRAW
Apr 15, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.60
Real-time Price: $0.165 info
Change: -$1.44 (-90%) info
Market Cap: $2.689M info
TRAW
Feb 19, 2026, 8:42 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $0.165 info
Change: -$1.33 (-89%) info
Market Cap: $2.689M info
TRAW
Jan 26, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.44
Real-time Price: $0.165 info
Change: -$2.28 (-93%) info
Market Cap: $2.689M info
TRAW
Jan 13, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.28
Real-time Price: $0.165 info
Change: -$1.12 (-87%) info
Market Cap: $2.689M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets